Skip To Main Content
Prakash Deedwania on Muck Rack

Prakash Deedwania

As seen in: Color Research & Application, Wiley Online Library, American Journal of Cardiovascular Drugs, JAMA (The Journal of the American Medical Association), JAMA: Journal of the American Medical Association, Medscape, The Lancet, Healio, Healio Cardiac/Vascular Intervention, International Journal of Cardiology
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Prakash

Contact Prakash, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Identification and outcomes of KDIGO‐defined chronic kidney disease in 1.4 million U.S. Veterans with heart failure

|
By Samir S. Patel Verified, Venkatesh Raman, Sijian Zhang, Prakash Deedwania
| Wiley Online Library Verified
Supporting Information Filename Description ejhf3210-sup-0001-Tables.docxWord 2007 document , 27.5 KB Appendix S1. Supporting Information. References 1, . Epidemiology of chronic kidney disease in heart failure. Heart Fail Clin 2008; 4: 387–399. https://doi.org/10.1016/j.hfc.2008.03.008 2, , , , , , et al. Association of chronic kidney disease with outcomes in chronic heart failure: A propensity-matched study. Nephrol Dial Transplant 2009; 24: 186–193.
Open in Who Shared Issue with article?

Efficacy and Safety of PCSK9 Inhibition With Evolocumab in Reducing Cardiovascular Events

|
By Prakash Deedwania, CHU Liege, Andre Scheen
| JAMA (The Journal of the American Medical Association) Verified
Original Investigation August 12, 2020 JAMA Cardiol. Published online August 12, 2020. doi:10.1001/jamacardio.2020.3151 Key Points Question Can further reduction of low-density lipoprotein cholesterol with evolocumab safely and effectively reduce the residual risk in patients with metabolic syndrome and stable atherosclerotic cardiovascular disease?
Open in Who Shared Issue with article?

β-Blocker Use and Clinical Outcomes in Stable Outpatients With and Without Coronary Artery Disease

|
By Sripal Bangalore, Gabriel Steg, Prakash Deedwania, Kevin Crowley Verified
| JAMA: Journal of the American Medical Association Verified
[Skip to Content Landing] Figure 1. Cumulative Incidence Curve for the Risk of Primary Outcome by β-Blocker Use Y-axis range shown in blue indicates event rate from 0% to 14%. The primary outcome was a composite of cardiovascular death, nonfatal MI, or nonfatal stroke. CAD indicates coronary artery disease; HR, hazard ratio; and MI, myocardial infarction. Figure 2.
Open in Who Shared Issue with article?
See all 14 licensed articles (15 Total)